Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C2H7N5 |
| Molecular Weight | 101.1105 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)NC(N)=N
InChI
InChIKey=XNCOSPRUTUOJCJ-UHFFFAOYSA-N
InChI=1S/C2H7N5/c3-1(4)7-2(5)6/h(H7,3,4,5,6,7)
Biguanide has been investigated for the treatment of Diabetes Mellitus. The term "biguanidine" often refers specifically to a class of drugs that have a broad range of medical indications. Besides recent experiments have shown that biguanide could be a modifiable pharmacophore for the synthesis of therapeutic cysteinyl cathepsins inhibitors with a wide range of potencies and specificities. It is known that excessive activities of cysteinyl cathepsins contribute to the progress of many diseases.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. | 2003-09 |
|
| Antidiabetic and antimalarial biguanide drugs are metal-interactive antiproteolytic agents. | 2003-08-15 |
|
| Effectiveness of low-dose intramuscular anti-VHB immune globulin in the prophylaxis of viral B hepatitis reinfection after liver transplantation: preliminary report. | 2003-08 |
|
| Prophylaxis of recurrent hepatitis B virus by vaccination after liver transplant: preliminary results. | 2003-08 |
|
| Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. | 2003-08 |
|
| Cardioprotection with pioglitazone is abolished by nitric oxide synthase inhibitor in ischemic rabbit hearts--comparison of the effects of pioglitazone and metformin. | 2003-07-25 |
|
| New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione. | 2003-07 |
|
| Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan. | 2003-07 |
|
| Interruption of HBV intrauterine transmission: a clinical study. | 2003-07 |
|
| HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. | 2003-07 |
|
| [Medication of the month. Glucovance in type 2 diabetes, a fixed combination of metformin-glibenclamide for the treatment of a bipolar metabolic disease]. | 2003-06 |
|
| Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. | 2003-06 |
|
| Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant. | 2003-06 |
|
| Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. | 2003-06 |
|
| A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. | 2003-06 |
|
| Plasma interleukin 8 concentrations in obese subjects with impaired glucose tolerance. | 2003-05-16 |
|
| A randomized control trial on interruption of HBV transmission in uterus. | 2003-05 |
|
| [Efficacy of recombinant hepatitis B vaccine and low-dose hepatitis B immune globulin in preventing mother-infant transmission of hepatitis B virus infection]. | 2003-05 |
|
| Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones. | 2003-05 |
|
| Insulin resistance syndrome. Description, pathogenesis, and management. | 2003-05 |
|
| Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. | 2003-05 |
|
| Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature. | 2003-05 |
|
| Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. | 2003-04-27 |
|
| Mild acute renal failure potentiates metformin accumulation in the diabetic rat kidney without further impairment of renal function. | 2003-04 |
|
| Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. | 2003-04 |
|
| Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. | 2003-04 |
|
| Breastfeeding does not pose any additional risk of immunoprophylaxis failure on infants of HBV carrier mothers. | 2003-03 |
|
| Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation. | 2003-03 |
|
| Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. | 2003-03 |
|
| Role of 0.02% polyhexamethylene biguanide and 1% povidone iodine in experimental Aspergillus keratitis. | 2003-03 |
|
| Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. | 2003-02-15 |
|
| Cissus sicyoides (princess vine) in the long-term treatment of streptozotocin-diabetic rats. | 2003-02 |
|
| The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. | 2003-01 |
|
| Metformin: new understandings, new uses. | 2003 |
|
| New options in the treatment of chronic hepatitis. | 2003 |
|
| A pilot study on the combined therapy of granulocyte-macrophage colony-stimulating factor and hepatitis B vaccine on chronic hepatitis B virus carrier children. | 2002-12 |
|
| Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. | 2002-11-15 |
|
| Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. | 2002-11-01 |
|
| Combination of HBIG and lamivudine-resistant mutations: a formula for trouble? | 2002-11 |
|
| Prevention of recurrent hepatitis B post-liver transplantation. | 2002-10 |
|
| Hepatitis B: progress in the last 15 years. | 2002-10 |
|
| Evolving experience of hepatitis B virus prophylaxis in liver transplantation. | 2002-09 |
|
| Mechanism of peripheral blood mononuclear cell invasion by HBV on artificial immunization in newborns. | 2002-09 |
|
| [Clinical usefulness of treatment with biguanide and insulin]. | 2002-09 |
|
| Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. | 2002-09 |
|
| Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. | 2002-08 |
|
| Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. | 2002-07-20 |
|
| Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. | 2002-07 |
|
| Trends in oral antihyperglycemic and insulin use in the Nova Scotia senior population (1993-1999). | 2002 |
|
| A study of the pharmacokinetic profile of low-dose hepatitis B immune globulin in long-term liver transplant recipients for chronic hepatitis B infection. | 2001-05 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3095
Created by
admin on Mon Mar 31 21:07:06 GMT 2025 , Edited by admin on Mon Mar 31 21:07:06 GMT 2025
|
PRIMARY | |||
|
56-03-1
Created by
admin on Mon Mar 31 21:07:06 GMT 2025 , Edited by admin on Mon Mar 31 21:07:06 GMT 2025
|
PRIMARY | |||
|
200-251-8
Created by
admin on Mon Mar 31 21:07:06 GMT 2025 , Edited by admin on Mon Mar 31 21:07:06 GMT 2025
|
PRIMARY | |||
|
BIGUANIDE
Created by
admin on Mon Mar 31 21:07:06 GMT 2025 , Edited by admin on Mon Mar 31 21:07:06 GMT 2025
|
PRIMARY | |||
|
m2488
Created by
admin on Mon Mar 31 21:07:06 GMT 2025 , Edited by admin on Mon Mar 31 21:07:06 GMT 2025
|
PRIMARY | Merck Index | ||
|
FB4Q52I9K2
Created by
admin on Mon Mar 31 21:07:06 GMT 2025 , Edited by admin on Mon Mar 31 21:07:06 GMT 2025
|
PRIMARY | |||
|
DB13100
Created by
admin on Mon Mar 31 21:07:06 GMT 2025 , Edited by admin on Mon Mar 31 21:07:06 GMT 2025
|
PRIMARY | |||
|
DTXSID7074664
Created by
admin on Mon Mar 31 21:07:06 GMT 2025 , Edited by admin on Mon Mar 31 21:07:06 GMT 2025
|
PRIMARY | |||
|
300000051419
Created by
admin on Mon Mar 31 21:07:06 GMT 2025 , Edited by admin on Mon Mar 31 21:07:06 GMT 2025
|
PRIMARY | |||
|
5939
Created by
admin on Mon Mar 31 21:07:06 GMT 2025 , Edited by admin on Mon Mar 31 21:07:06 GMT 2025
|
PRIMARY | |||
|
FB4Q52I9K2
Created by
admin on Mon Mar 31 21:07:06 GMT 2025 , Edited by admin on Mon Mar 31 21:07:06 GMT 2025
|
PRIMARY | |||
|
1918319
Created by
admin on Mon Mar 31 21:07:06 GMT 2025 , Edited by admin on Mon Mar 31 21:07:06 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
